기업 프로필 · Healthcare

Simulations Plus Inc

SLP · 미국
거래소
미국
국가 / 지역
USA
상장일
1997년 6월 18일
직원 수
212
현재가
$18.33
실시간 · 2026년 7월 27일
적정 매수가
≤ $12.5
안전마진 진입가
베일리 성장 점수
38/100
다소 약함
내재가치 · 3단계 구간 현재가 $18.33 실시간 · 낙관적 내재가치 구간 내 · 상당한 기대가 선반영

종합 밸류에이션 구간 · 보수적 $11–$12.5 / 적정 $14–$16 / 낙관적 $17.6–$18.6. $18.33 기준, 낙관적 내재가치 구간 내 · 상당한 기대가 선반영.

보고서 발행 시 $18.14(2026년 6월 26일)

2026년 6월 28일 M&A Confirmed

Simulations Plus agrees to be acquired by Altaris

Simulations Plus said it agreed to be acquired by Altaris and is expected to combine with CCG at closing.

Possible impact:May affect merger-premium expectations and pricing of regulatory, shareholder approval and closing risks.

Simulations PlusView source
2026년 4월 9일 Earnings Confirmed

SLP Earnings Presentation Q2FY26

The company posted its fiscal Q2 2026 earnings presentation and webcast materials.

Possible impact:May affect investor views on growth, margins, and the fiscal-year operating cadence.

Simulations PlusView source

Automatically summarized from public sources; for context only, not investment advice.

시가총액US$3.71억
매출 (TTM)US$8205.8만
EBITDAUS$1501.6만
순이익률9.88%
ROE6.17%
PER (TTM)45.85
선행 PER21.65
PEG9.88
EPSUS$0.40
52주 범위US$11.09 – US$21.01
애널리스트 목표주가US$17.25
애널리스트 평가4.7 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.